Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
Cancer Chemother Pharmacol
.
2022 Jun;89(6):839.
doi: 10.1007/s00280-022-04421-7.
Authors
Jennifer E Hibma
1
,
Melissa O'Gorman
2
,
Sunil Nepal
#
3
4
,
Sylvester Pawlak
5
,
Katherine Ginman
6
,
Yazdi K Pithavala
7
Affiliations
1
Pfizer (Clinical Pharmacology Oncology), La Jolla, 10555 Science Center Drive, CB10-2727, San Diego, CA, 92121, USA. Jennifer.e.hibma@pfizer.com.
2
Pfizer (Pharmacometrics Oncology), Groton, CT, USA.
3
Pfizer (Statistics Oncology), Groton, CT, USA.
4
Independent Statistical Consultant, Schwenksville, PA, USA.
5
Pfizer (Clinical Development and Operations), New Haven, CT, USA.
6
Pfizer (Clinical Development and Operations), South Lyon, MI, USA.
7
Pfizer (Clinical Pharmacology Oncology), La Jolla, 10555 Science Center Drive, CB10-2727, San Diego, CA, 92121, USA.
#
Contributed equally.
PMID:
35303141
PMCID:
PMC9135853
DOI:
10.1007/s00280-022-04421-7
No abstract available
Publication types
Published Erratum